Abeona Therapeutics Inc.

NASDAQ:ABEO

Biotechnology

Healthcare
$2.73 +1.06%

+$0.06 today

Market cap
$156.01M
Beta
1.35
P/E (TTM)
4.9
EPS (TTM)
$1.17
52W Low $4.00High $7.54

Volume 1.71M

Average 1.12M

ABEO Depreciation & Amortization

Non-cash expense that spreads the cost of physical and intangible assets over their useful lives.

Abeona Therapeutics Inc.NASDAQ: ABEO

Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026

Depreciation & amortization grows, but more slowly than its trailing trend

Q1 FY2026 depreciation & amortization of $869K rose 6.6% year over year, behind the +20.6% change in trailing-twelve-month depreciation & amortization. Sequentially, it fell 20.4% from the prior quarter. Over 3 fiscal years it compounded at -8.0% a year.

Context

  • Depreciation & amortization amounted to 61.2% of revenue in FY2025.
  • Depreciation & amortization increased in 1 of the last 3 fiscal years.

What to watch

Whether quarterly growth recovers from +6.6% toward the trailing-twelve-month pace of +20.6%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$869K-20.4% QoQ
Last fiscal yearDec 2025
$3.56M+22.6% YoY
LTMMar 2026
$3.62M+20.6% YoY
Depreciation & Amortization past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+6.6%——
1 year+22.6%——
3-year CAGR-8.0%——
5-year CAGR——
10-year CAGR——

Depreciation & Amortization history

USD · from the income statement

Latest · FY2025
3.56M USD
Year-over-year change
+22.6%
4-year CAGR
-5.5%

Depreciation & Amortization vs competitors

How ABEO compares with its peers on the latest reported figures

  • ABEO's LTM Mar 2026 depreciation & amortization of $3.62M is the 5th highest of the 10 companies compared; the peer median is $2.88M.
  • Its year-over-year change of +20.6% is the highest of 9, against a peer median of -11.4%.
  • Depreciation & amortization amounts to 24.9% of revenue for ABEO, versus a peer median of 9.9%.
ABEO Competitors Peer median
Depreciation & Amortization for ABEO and competitors
Company Period LTM YoY 3-year CAGR% of revenue
PBYIPuma Biotechnology, Inc.LTM Mar 2026$10.64M -6.8%+3.6%4.7%
TNYATenaya Therapeutics, Inc.LTM Mar 2026$7.54M -16.0%-1.1%3350.2%
HUMAHumacyte, Inc.LTM Mar 2026$7.3M +0.4%-3.6%362.3%
VYGRVoyager Therapeutics, Inc.LTM Mar 2026$3.98M -12.6%-13.1%10.9%
ABEOAbeona Therapeutics Inc.LTM Mar 2026$3.62M +20.6%-8.0%24.9%
ARCTArcturus Therapeutics Holdings Inc.LTM Mar 2026$2.88M -16.2%+25.6%6.4%
FHTXFoghorn Therapeutics Inc.LTM Mar 2026$2.79M -10.3%+0.1%9.9%
ASMBAssembly Biosciences, Inc.LTM Mar 2026$122K -6.2%-36.3%0.2%
ELDNEledon Pharmaceuticals, Inc.LTM Mar 2026$81K -69.3%-5.7%—
SGMTSagimet Biosciences Inc.LTM Mar 2026$0 ———
Peer median (excluding ABEO) $2.88M-11.4%-2.4%9.9%

Competitors are the stored peer set for ABEO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue3M1.41M3.5M05.82M
Cost of Revenue0450K1.61M2.91M1.53M
Gross Profit3M964K1.9M(2.91M)4.29M
Gross Margin100.0%68.2%54.1%—73.7%
Research & Development38.73M28.97M31.09M34.36M26.81M
Selling, General & Admin21.64M17.26M19M29.85M65.03M
Operating Expenses92.84M51.88M49.03M61.3M93.74M
Depreciation & Amortization4.46M4.58M3.2M2.91M3.56M
EBITDA(76.82M)(34.38M)(50.57M)(56.62M)78.59M
EBITDA Margin-2560.5%-2431.6%-1444.9%—1350.3%
Operating Income(89.84M)(50.92M)(47.14M)(64.21M)(89.45M)
Operating Margin-2994.5%-3600.8%-1346.7%—-1536.9%
Interest Income40K431K2.12M4.25M5.56M
Interest Expense3.66M736K418K4.21M3.74M
Other Income / Expenses4.9M11.22M(7.05M)477K160.73M
Income Before Tax(84.94M)(39.7M)(54.19M)(63.73M)71.28M
Pre-Tax Margin-2831.2%-2807.4%-1548.2%—1224.8%
Income Tax Expense0000100K
Net Income(84.94M)(39.7M)(54.19M)(63.73M)71.18M
Net Margin-2831.2%-2807.4%-1548.2%—1223.1%
EPS (Basic)(21.50)(5.53)(2.53)(1.55)1.34
EPS (Diluted)(21.50)(5.53)(2.53)(1.55)1.01
Weighted Avg Shares3.94M7.86M21.38M41.05M52.95M
Weighted Avg Shares (Diluted)3.94M7.86M21.38M41.05M66.14M

Abeona Therapeutics Inc.

NASDAQ:ABEO

Intrinsic Alpha fair value

Locked

Current Price

$2.73

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.